Company: PFSA
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112723
Chunk: 8

Company: Profusa, Inc.
Filing Date: 2025-11-19
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---
  
     1,826 

    Net increase (decrease) in cash 
     2,818  
     (2)
  
    Cash at the beginning of the period 
     191  
     142 
  
    Cash at the end of the period 
     3,009  
     140 

    Supplemental disclosures of non-cash investing and financing information: 

    Assumption of net liabilities of Northview 
     12,346  
     — 
  
    Issuance in shares in connection with convertible note 
     7,254  
     — 
  
    Increase (decrease) in unpaid deferred offering costs 
     —  
     (32)
  
    Issuance in shares in connection with ELOC transaction costs 
     3,537  
     — 
  
    Issuance of warrants in connection with ELOC costs 
     982  

    Issuance in shares in connection with non-recourse note to employees 
     428  
     — 
  
    Conversion of preferred stock into common stock 
     65,149  
     — 
  
    Issuance of HCW warrants in lieu of cash payment 
     330  
     — 
  
    Conversion of debt to equity 
     46,891  
     — 

    Supplemental disclosure of cash flow information: 

    Cash paid for interest 
     250  
     — 
  
    Cash paid for taxes 
     13  
     — 

The accompanying notes are an integral part of
these condensed consolidated financial statements.

5

PROFUSA, INC. AND SUBSIDIARY 

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (UNAUDITED)

Note 1 — Organization, Description of Business, Going Concern
and Significant Risks and Uncertainties

Description of Business

Profusa, Inc. (the “Company”) was incorporated in the state
of California on May 11, 2009. The Company is engaged in the development of a new generation of biointegrated sensors that potentially
empowers the individual with the ability to monitor their unique body chemistry.

The Company’s technology enables the development of bioengineered
sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal
and medical use. The Company